Fluidigm Corporation (ticker: FLDM) — Q3 2020 Form 10-Q
Entity and period: The filing identifies the registrant as Fluidigm Corporation, not Standard BioTools Inc. It reports the quarter and nine months ended September 30, 2020; financial statements are unaudited. Amounts below are in U.S. dollars unless noted.
Business context and results
Fluidigm developed and sold life-sciences research instruments, consumables, and services, including microfluidics and mass cytometry products. COVID-19-related testing demand supported microfluidics sales, while pandemic-related customer disruptions delayed some mass cytometry instrument purchases.
| Metric | Q3 2020 | Q3 2019 | Nine months 2020 | Nine months 2019 |
|---|---|---|---|---|
| Revenue | $39.9m | $26.5m | $93.5m | $84.8m |
| Operating loss | $5.5m | $13.8m | $34.1m | $42.7m |
| Net loss | $6.0m | $12.9m | $35.0m | $52.1m |
| Net loss per share | $0.08 | $0.19 | $0.49 | $0.79 |
| Product and service gross margin | 58.9% | 52.6% | 55.6% | 54.6% |
Q3 revenue rose 50% year over year; nine-month revenue increased 10%. Q3 product revenue grew 41%, while nine-month product revenue declined 5%, principally reflecting weaker mass cytometry instrument sales. Nine-month service revenue grew 4%. Americas revenue was $52.4m for the nine months, up 49%; EMEA and Asia-Pacific revenue declined 17% each.
Financial position, cash flow, and capital
- At September 30, cash and cash equivalents were $72.3m, restricted cash was $1.0m, and short-term investments were nil. Total assets were $323.0m and stockholders’ equity was $152.0m.
- Nine-month operating cash outflow was $11.7m, versus $29.7m in 2019. Investing activities provided $40.8m, including NIH grant receipts and investment maturities; financing provided $20.4m, primarily from the ATM share offering. Cash, cash equivalents, and restricted cash increased $49.6m.
- Convertible notes had $56.1m aggregate principal outstanding ($54.1m net carrying value): $55.0m of 5.25% notes due 2024 and $1.1m of 2.75% notes due 2034. The $15.0m revolving facility, extended to August 2022, was undrawn; the company reported covenant compliance.
- The company issued 2.5m shares through its ATM program in Q3 for $20.9m gross and approximately $20.1m net proceeds. Shares outstanding rose to 74.1m from 70.0m at year-end 2019.
- Operating lease liabilities totaled $41.3m, largely reflecting the new approximately ten-year South San Francisco headquarters lease.
Material changes, outlook, and risks
- COVID-19 and demand: Management estimated about 10% of customers remained closed or at reduced capacity at September-end, down from 30–40% in June. Research activity recovery remained uncertain, and mass cytometry instrument sales were delayed. COVID-19 applications supported microfluidics instruments and consumables and mass cytometry reagents.
- Government funding and investment: The NIH RADx contract has a potential value of up to $34.0m subject to milestones. By September 30, $18.6m of milestones were considered reasonably assured; $11.2m had been received, with $7.5m receivable. Management expected approximately $30.0m of capital expenditures over the next two quarters for Singapore capacity expansion, principally supported by the contract. Completion was expected by the end of 2021. NIH may terminate for convenience; specified default-related delays can trigger liquidated damages.
- Management outlook: No specific revenue or earnings guidance is provided. Management stated existing cash, cash equivalents, and investments should fund working capital and capital expenditures for at least 18 months, while warning that lower cash generation or higher spending could require additional capital. Temporary salary reductions ended in Q3; hiring remained constrained.
- Unusual revenue items: Nine-month revenue included $6.2m from a new development agreement (up to $11.7m in payments) and $3.1m of license revenue from an intellectual-property settlement. Grant revenue was $2.1m for the nine months. These items contributed to reported growth and should be distinguished from recurring product and service sales.
- Other risks and contingencies: The FDA’s EUA for the saliva-based Advanta Dx SARS-CoV-2 assay is tied to the public-health emergency and may end or be revoked. The NIH contract is milestone-dependent. A September 2020 securities class action sought unspecified damages; the company said it considered the claims meritless and intended to defend them. COVID-19 effects, customer concentration, competition, single-source supply, and potential additional equity dilution were also disclosed risks.
Investor verification priorities
- Confirm the registrant identity and relationship, if any, between this Fluidigm filing and the requested Standard BioTools Inc. entity.
- Assess how much reported growth and cash support came from COVID-related sales, NIH funding, development revenue, and the one-time license settlement.
- Track RADx milestone acceptance, grant collections, planned capacity spending, and any contract termination or performance obligations.
- Review operating cash burn, the 18-month liquidity assertion, noteholder put rights beginning in February 2021, and potential funding or dilution needs.
- Monitor the SARS-CoV-2 EUA status, customer recovery, delayed mass cytometry demand, and the securities litigation.